Glatiramer0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Glatiramer — research data
Regulatory statusFDA-approved (Copaxone)
NCAA D1Permitted
Overview
About Glatiramer
Mechanism of action
Random amino acid copolymer modifying immune response to myelin antigens via T-cell modulation
Safety profile
Injection site reactions, post-injection flushing, chest pain, lipoatrophy · Decades of MS use; injection site reactions; post-injection reaction syndrome; excellent long-term safety
Related pages